United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

NASDAQ:UTHR

United Therapeutics Corporation

Last Close

236.93

19/04 20:00

Market Cap

11.20B

Beta: 0.60

Volume Today

361.86K

Avg: 596.50K

PE Ratio

11.12

PFCF: 13.12

locale

market

industry

website

ipo date

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

Metrics

Please Sign In To Use The Chat